Global Multiple Sclerosis Treatment Market research

Multiple Sclerosis Treatment Comprehensive Study by Type (Immunomodulators (Ponesimod, Glatopa, Copaxone, Others), Immunosuppressant (Cladribine, Others), Corticosteroids (Prednisone, Methylprednisolone), Beta interferons (Betaseron, Others)), Application (Veterinary Hospitals, Veterinary Clinics, Research Institutions), Multiple Sclerosis (Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Primary Progressive MS (PPMS), Others), Distribution Channel (Healthcare Providers, Online Pharmacies, Medical Clinics, Others), Administration (Injectable, Intravenous, Oral) Players and Region - Global Market Outlook to 2030

Multiple Sclerosis Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Multiple Sclerosis Treatment
Nearly 1 million people are living with Multiple Sclerosis (MS) in the United States, according to a study funded by the National MS Society. This is more than twice the original estimate and means solutions for MS are now twice as important. Multiple sclerosis (MS) is an unpredictable disease of the central nervous system that disturbs the flow of information inside the brain and among the brain and body. According to the national multiple sclerosis society, Most people with multiple sclerosis are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR4.9%


Growing focus on drug discovery, speed up delivery of new treatments for patients, the introduction of highly efficient therapies, a multiplicity of new drugs entering the market, huge R&D activities & investments in multiple sclerosis (MS) therapeutics clinical development are key factors contributing to Growth of Multiple Sclerosis Therapeutics during the forecast period. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Multiple Sclerosis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Teva (Israel), Biogen(United States), Genzyme (Sanofi), GlaxoSmithKline(United Kingdom), Merck Serono(Germany), Novartis(Switzerland), Pfizer (United States) and Abbvie (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Acorda Therapeutics(United States) and Bayer HealthCare (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Multiple Sclerosis Treatment market by Type (Immunomodulators (Ponesimod, Glatopa, Copaxone, Others), Immunosuppressant (Cladribine, Others), Corticosteroids (Prednisone, Methylprednisolone) and Beta interferons (Betaseron, Others)), Application (Veterinary Hospitals, Veterinary Clinics and Research Institutions) and Region.



On the basis of geography, the market of Multiple Sclerosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Multiple Sclerosis, the sub-segment i.e. Clinically Isolated Syndrome (CIS) will boost the Multiple Sclerosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Healthcare Providers will boost the Multiple Sclerosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Administration , the sub-segment i.e. Injectable will boost the Multiple Sclerosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Growing Number Of Multiple Sclerosis Incidences key Driving Factor of Growth

Market Growth Drivers:
Rising Awareness Among The People, Development In The Drugs And Therapeutics Sector

Challenges:
Key Competition R&D for new Solutions in between Key Players

Restraints:
High Cost of Treatment

Opportunities:
Increasing Investments In The Healthcare Sector And involvement Of Government And Support Is Offering The Huge Opportunities Of Growth In The Market

Market Leaders and their expansionary development strategies

In July 2019 ,It is exciting news for MS patients in China that Gilenya has customary fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent® demonstrate our commitment to Chinese patients.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Multiple Sclerosis Treatment Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Immunomodulators (Ponesimod, Glatopa, Copaxone, Others)
  • Immunosuppressant (Cladribine, Others)
  • Corticosteroids (Prednisone, Methylprednisolone)
  • Beta interferons (Betaseron, Others)
By Application
  • Veterinary Hospitals
  • Veterinary Clinics
  • Research Institutions
By Multiple Sclerosis
  • Clinically Isolated Syndrome (CIS)
  • Relapsing-Remitting MS (RRMS)
  • Primary Progressive MS (PPMS)
  • Others

By Distribution Channel
  • Healthcare Providers
  • Online Pharmacies
  • Medical Clinics
  • Others

By Administration
  • Injectable
  • Intravenous
  • Oral

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness Among The People, Development In The Drugs And Therapeutics Sector
    • 3.3. Market Challenges
      • 3.3.1. Key Competition R&D for new Solutions in between Key Players
    • 3.4. Market Trends
      • 3.4.1. The Growing Number Of Multiple Sclerosis Incidences key Driving Factor of Growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Multiple Sclerosis Treatment, by Type, Application, Multiple Sclerosis, Distribution Channel, Administration and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Multiple Sclerosis Treatment (Value)
      • 5.2.1. Global Multiple Sclerosis Treatment by: Type (Value)
        • 5.2.1.1. Immunomodulators (Ponesimod, Glatopa, Copaxone, Others)
        • 5.2.1.2. Immunosuppressant (Cladribine, Others)
        • 5.2.1.3. Corticosteroids (Prednisone, Methylprednisolone)
        • 5.2.1.4. Beta interferons (Betaseron, Others)
      • 5.2.2. Global Multiple Sclerosis Treatment by: Application (Value)
        • 5.2.2.1. Veterinary Hospitals
        • 5.2.2.2. Veterinary Clinics
        • 5.2.2.3. Research Institutions
      • 5.2.3. Global Multiple Sclerosis Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Healthcare Providers
        • 5.2.3.2. Online Pharmacies
        • 5.2.3.3. Medical Clinics
        • 5.2.3.4. Others
      • 5.2.4. Global Multiple Sclerosis Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Multiple Sclerosis Treatment (Volume)
      • 5.3.1. Global Multiple Sclerosis Treatment by: Type (Volume)
        • 5.3.1.1. Immunomodulators (Ponesimod, Glatopa, Copaxone, Others)
        • 5.3.1.2. Immunosuppressant (Cladribine, Others)
        • 5.3.1.3. Corticosteroids (Prednisone, Methylprednisolone)
        • 5.3.1.4. Beta interferons (Betaseron, Others)
      • 5.3.2. Global Multiple Sclerosis Treatment by: Application (Volume)
        • 5.3.2.1. Veterinary Hospitals
        • 5.3.2.2. Veterinary Clinics
        • 5.3.2.3. Research Institutions
      • 5.3.3. Global Multiple Sclerosis Treatment by: Distribution Channel (Volume)
        • 5.3.3.1. Healthcare Providers
        • 5.3.3.2. Online Pharmacies
        • 5.3.3.3. Medical Clinics
        • 5.3.3.4. Others
      • 5.3.4. Global Multiple Sclerosis Treatment Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Multiple Sclerosis Treatment (Price)
      • 5.4.1. Global Multiple Sclerosis Treatment by: Type (Price)
  • 6. Multiple Sclerosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biogen(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genzyme (Sanofi)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline(United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck Serono(Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis(Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbvie (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Multiple Sclerosis Treatment Sale, by Type, Application, Multiple Sclerosis, Distribution Channel, Administration and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Multiple Sclerosis Treatment (Value)
      • 7.2.1. Global Multiple Sclerosis Treatment by: Type (Value)
        • 7.2.1.1. Immunomodulators (Ponesimod, Glatopa, Copaxone, Others)
        • 7.2.1.2. Immunosuppressant (Cladribine, Others)
        • 7.2.1.3. Corticosteroids (Prednisone, Methylprednisolone)
        • 7.2.1.4. Beta interferons (Betaseron, Others)
      • 7.2.2. Global Multiple Sclerosis Treatment by: Application (Value)
        • 7.2.2.1. Veterinary Hospitals
        • 7.2.2.2. Veterinary Clinics
        • 7.2.2.3. Research Institutions
      • 7.2.3. Global Multiple Sclerosis Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Healthcare Providers
        • 7.2.3.2. Online Pharmacies
        • 7.2.3.3. Medical Clinics
        • 7.2.3.4. Others
      • 7.2.4. Global Multiple Sclerosis Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Multiple Sclerosis Treatment (Volume)
      • 7.3.1. Global Multiple Sclerosis Treatment by: Type (Volume)
        • 7.3.1.1. Immunomodulators (Ponesimod, Glatopa, Copaxone, Others)
        • 7.3.1.2. Immunosuppressant (Cladribine, Others)
        • 7.3.1.3. Corticosteroids (Prednisone, Methylprednisolone)
        • 7.3.1.4. Beta interferons (Betaseron, Others)
      • 7.3.2. Global Multiple Sclerosis Treatment by: Application (Volume)
        • 7.3.2.1. Veterinary Hospitals
        • 7.3.2.2. Veterinary Clinics
        • 7.3.2.3. Research Institutions
      • 7.3.3. Global Multiple Sclerosis Treatment by: Distribution Channel (Volume)
        • 7.3.3.1. Healthcare Providers
        • 7.3.3.2. Online Pharmacies
        • 7.3.3.3. Medical Clinics
        • 7.3.3.4. Others
      • 7.3.4. Global Multiple Sclerosis Treatment Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Multiple Sclerosis Treatment (Price)
      • 7.4.1. Global Multiple Sclerosis Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Multiple Sclerosis Treatment: by Type(USD Million)
  • Table 2. Multiple Sclerosis Treatment Immunomodulators (Ponesimod, Glatopa, Copaxone, Others) , by Region USD Million (2018-2023)
  • Table 3. Multiple Sclerosis Treatment Immunosuppressant (Cladribine, Others) , by Region USD Million (2018-2023)
  • Table 4. Multiple Sclerosis Treatment Corticosteroids (Prednisone, Methylprednisolone) , by Region USD Million (2018-2023)
  • Table 5. Multiple Sclerosis Treatment Beta interferons (Betaseron, Others) , by Region USD Million (2018-2023)
  • Table 6. Multiple Sclerosis Treatment: by Application(USD Million)
  • Table 7. Multiple Sclerosis Treatment Veterinary Hospitals , by Region USD Million (2018-2023)
  • Table 8. Multiple Sclerosis Treatment Veterinary Clinics , by Region USD Million (2018-2023)
  • Table 9. Multiple Sclerosis Treatment Research Institutions , by Region USD Million (2018-2023)
  • Table 10. Multiple Sclerosis Treatment: by Distribution Channel(USD Million)
  • Table 11. Multiple Sclerosis Treatment Healthcare Providers , by Region USD Million (2018-2023)
  • Table 12. Multiple Sclerosis Treatment Online Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Multiple Sclerosis Treatment Medical Clinics , by Region USD Million (2018-2023)
  • Table 14. Multiple Sclerosis Treatment Others , by Region USD Million (2018-2023)
  • Table 15. South America Multiple Sclerosis Treatment, by Country USD Million (2018-2023)
  • Table 16. South America Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 17. South America Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 18. South America Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 19. South America Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 20. South America Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 21. Brazil Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 22. Brazil Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 23. Brazil Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 24. Brazil Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 25. Brazil Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 26. Argentina Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 27. Argentina Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 28. Argentina Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 29. Argentina Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 30. Argentina Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 31. Rest of South America Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 34. Rest of South America Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 35. Rest of South America Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 36. Asia Pacific Multiple Sclerosis Treatment, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 40. Asia Pacific Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 41. Asia Pacific Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 42. China Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 43. China Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 44. China Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 45. China Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 46. China Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 47. Japan Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 48. Japan Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 49. Japan Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 50. Japan Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 51. Japan Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 52. India Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 53. India Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 54. India Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 55. India Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 56. India Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 57. South Korea Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 58. South Korea Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 59. South Korea Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 60. South Korea Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 61. South Korea Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 62. Taiwan Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 63. Taiwan Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 64. Taiwan Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 65. Taiwan Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 66. Taiwan Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 67. Australia Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 68. Australia Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 69. Australia Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 70. Australia Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 71. Australia Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 73. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 77. Europe Multiple Sclerosis Treatment, by Country USD Million (2018-2023)
  • Table 78. Europe Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 79. Europe Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 80. Europe Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 81. Europe Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 82. Europe Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 83. Germany Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 84. Germany Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 85. Germany Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 86. Germany Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 87. Germany Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 88. France Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 89. France Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 90. France Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 91. France Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 92. France Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 93. Italy Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 94. Italy Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 95. Italy Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 96. Italy Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 97. Italy Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 98. United Kingdom Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 99. United Kingdom Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 100. United Kingdom Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 101. United Kingdom Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 102. United Kingdom Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 103. Netherlands Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 104. Netherlands Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 105. Netherlands Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 106. Netherlands Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 107. Netherlands Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 108. Rest of Europe Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 109. Rest of Europe Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 110. Rest of Europe Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 111. Rest of Europe Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 112. Rest of Europe Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 113. MEA Multiple Sclerosis Treatment, by Country USD Million (2018-2023)
  • Table 114. MEA Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 115. MEA Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 116. MEA Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 117. MEA Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 118. MEA Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 119. Middle East Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 120. Middle East Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 121. Middle East Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 122. Middle East Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 123. Middle East Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 124. Africa Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 125. Africa Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 126. Africa Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 127. Africa Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 128. Africa Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 129. North America Multiple Sclerosis Treatment, by Country USD Million (2018-2023)
  • Table 130. North America Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 131. North America Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 132. North America Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 133. North America Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 134. North America Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 135. United States Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 136. United States Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 137. United States Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 138. United States Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 139. United States Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 140. Canada Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 141. Canada Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 142. Canada Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 143. Canada Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 144. Canada Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 145. Mexico Multiple Sclerosis Treatment, by Type USD Million (2018-2023)
  • Table 146. Mexico Multiple Sclerosis Treatment, by Application USD Million (2018-2023)
  • Table 147. Mexico Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2018-2023)
  • Table 148. Mexico Multiple Sclerosis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 149. Mexico Multiple Sclerosis Treatment, by Administration USD Million (2018-2023)
  • Table 150. Multiple Sclerosis Treatment Sales: by Type(K Units)
  • Table 151. Multiple Sclerosis Treatment Sales Immunomodulators (Ponesimod, Glatopa, Copaxone, Others) , by Region K Units (2018-2023)
  • Table 152. Multiple Sclerosis Treatment Sales Immunosuppressant (Cladribine, Others) , by Region K Units (2018-2023)
  • Table 153. Multiple Sclerosis Treatment Sales Corticosteroids (Prednisone, Methylprednisolone) , by Region K Units (2018-2023)
  • Table 154. Multiple Sclerosis Treatment Sales Beta interferons (Betaseron, Others) , by Region K Units (2018-2023)
  • Table 155. Multiple Sclerosis Treatment Sales: by Application(K Units)
  • Table 156. Multiple Sclerosis Treatment Sales Veterinary Hospitals , by Region K Units (2018-2023)
  • Table 157. Multiple Sclerosis Treatment Sales Veterinary Clinics , by Region K Units (2018-2023)
  • Table 158. Multiple Sclerosis Treatment Sales Research Institutions , by Region K Units (2018-2023)
  • Table 159. Multiple Sclerosis Treatment Sales: by Distribution Channel(K Units)
  • Table 160. Multiple Sclerosis Treatment Sales Healthcare Providers , by Region K Units (2018-2023)
  • Table 161. Multiple Sclerosis Treatment Sales Online Pharmacies , by Region K Units (2018-2023)
  • Table 162. Multiple Sclerosis Treatment Sales Medical Clinics , by Region K Units (2018-2023)
  • Table 163. Multiple Sclerosis Treatment Sales Others , by Region K Units (2018-2023)
  • Table 164. South America Multiple Sclerosis Treatment Sales, by Country K Units (2018-2023)
  • Table 165. South America Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 166. South America Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 167. South America Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 168. South America Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 169. South America Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 170. Brazil Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 171. Brazil Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 172. Brazil Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 173. Brazil Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 174. Brazil Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 175. Argentina Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 176. Argentina Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 177. Argentina Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 178. Argentina Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 179. Argentina Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 180. Rest of South America Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 181. Rest of South America Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 182. Rest of South America Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 183. Rest of South America Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 184. Rest of South America Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 185. Asia Pacific Multiple Sclerosis Treatment Sales, by Country K Units (2018-2023)
  • Table 186. Asia Pacific Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 187. Asia Pacific Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 188. Asia Pacific Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 189. Asia Pacific Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 190. Asia Pacific Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 191. China Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 192. China Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 193. China Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 194. China Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 195. China Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 196. Japan Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 197. Japan Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 198. Japan Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 199. Japan Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 200. Japan Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 201. India Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 202. India Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 203. India Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 204. India Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 205. India Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 206. South Korea Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 207. South Korea Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 208. South Korea Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 209. South Korea Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 210. South Korea Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 211. Taiwan Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 212. Taiwan Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 213. Taiwan Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 214. Taiwan Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 215. Taiwan Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 216. Australia Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 217. Australia Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 218. Australia Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 219. Australia Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 220. Australia Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 221. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 222. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 223. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 224. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 225. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 226. Europe Multiple Sclerosis Treatment Sales, by Country K Units (2018-2023)
  • Table 227. Europe Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 228. Europe Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 229. Europe Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 230. Europe Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 231. Europe Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 232. Germany Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 233. Germany Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 234. Germany Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 235. Germany Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 236. Germany Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 237. France Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 238. France Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 239. France Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 240. France Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 241. France Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 242. Italy Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 243. Italy Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 244. Italy Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 245. Italy Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 246. Italy Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 247. United Kingdom Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 248. United Kingdom Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 249. United Kingdom Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 250. United Kingdom Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 251. United Kingdom Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 252. Netherlands Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 253. Netherlands Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 254. Netherlands Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 255. Netherlands Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 256. Netherlands Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 257. Rest of Europe Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 258. Rest of Europe Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 259. Rest of Europe Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 260. Rest of Europe Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 261. Rest of Europe Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 262. MEA Multiple Sclerosis Treatment Sales, by Country K Units (2018-2023)
  • Table 263. MEA Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 264. MEA Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 265. MEA Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 266. MEA Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 267. MEA Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 268. Middle East Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 269. Middle East Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 270. Middle East Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 271. Middle East Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 272. Middle East Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 273. Africa Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 274. Africa Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 275. Africa Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 276. Africa Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 277. Africa Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 278. North America Multiple Sclerosis Treatment Sales, by Country K Units (2018-2023)
  • Table 279. North America Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 280. North America Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 281. North America Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 282. North America Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 283. North America Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 284. United States Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 285. United States Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 286. United States Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 287. United States Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 288. United States Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 289. Canada Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 290. Canada Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 291. Canada Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 292. Canada Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 293. Canada Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 294. Mexico Multiple Sclerosis Treatment Sales, by Type K Units (2018-2023)
  • Table 295. Mexico Multiple Sclerosis Treatment Sales, by Application K Units (2018-2023)
  • Table 296. Mexico Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2018-2023)
  • Table 297. Mexico Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2018-2023)
  • Table 298. Mexico Multiple Sclerosis Treatment Sales, by Administration K Units (2018-2023)
  • Table 299. Multiple Sclerosis Treatment: by Type(USD/Units)
  • Table 300. Company Basic Information, Sales Area and Its Competitors
  • Table 301. Company Basic Information, Sales Area and Its Competitors
  • Table 302. Company Basic Information, Sales Area and Its Competitors
  • Table 303. Company Basic Information, Sales Area and Its Competitors
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Multiple Sclerosis Treatment: by Type(USD Million)
  • Table 309. Multiple Sclerosis Treatment Immunomodulators (Ponesimod, Glatopa, Copaxone, Others) , by Region USD Million (2025-2030)
  • Table 310. Multiple Sclerosis Treatment Immunosuppressant (Cladribine, Others) , by Region USD Million (2025-2030)
  • Table 311. Multiple Sclerosis Treatment Corticosteroids (Prednisone, Methylprednisolone) , by Region USD Million (2025-2030)
  • Table 312. Multiple Sclerosis Treatment Beta interferons (Betaseron, Others) , by Region USD Million (2025-2030)
  • Table 313. Multiple Sclerosis Treatment: by Application(USD Million)
  • Table 314. Multiple Sclerosis Treatment Veterinary Hospitals , by Region USD Million (2025-2030)
  • Table 315. Multiple Sclerosis Treatment Veterinary Clinics , by Region USD Million (2025-2030)
  • Table 316. Multiple Sclerosis Treatment Research Institutions , by Region USD Million (2025-2030)
  • Table 317. Multiple Sclerosis Treatment: by Distribution Channel(USD Million)
  • Table 318. Multiple Sclerosis Treatment Healthcare Providers , by Region USD Million (2025-2030)
  • Table 319. Multiple Sclerosis Treatment Online Pharmacies , by Region USD Million (2025-2030)
  • Table 320. Multiple Sclerosis Treatment Medical Clinics , by Region USD Million (2025-2030)
  • Table 321. Multiple Sclerosis Treatment Others , by Region USD Million (2025-2030)
  • Table 322. South America Multiple Sclerosis Treatment, by Country USD Million (2025-2030)
  • Table 323. South America Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 324. South America Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 325. South America Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 326. South America Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 327. South America Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 328. Brazil Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 329. Brazil Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 330. Brazil Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 331. Brazil Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 332. Brazil Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 333. Argentina Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 334. Argentina Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 335. Argentina Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 336. Argentina Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 337. Argentina Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 338. Rest of South America Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 339. Rest of South America Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 340. Rest of South America Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 341. Rest of South America Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 342. Rest of South America Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 343. Asia Pacific Multiple Sclerosis Treatment, by Country USD Million (2025-2030)
  • Table 344. Asia Pacific Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 345. Asia Pacific Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 346. Asia Pacific Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 347. Asia Pacific Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 348. Asia Pacific Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 349. China Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 350. China Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 351. China Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 352. China Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 353. China Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 354. Japan Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 355. Japan Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 356. Japan Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 357. Japan Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 358. Japan Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 359. India Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 360. India Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 361. India Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 362. India Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 363. India Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 364. South Korea Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 365. South Korea Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 366. South Korea Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 367. South Korea Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 368. South Korea Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 369. Taiwan Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 370. Taiwan Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 371. Taiwan Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 372. Taiwan Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 373. Taiwan Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 374. Australia Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 375. Australia Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 376. Australia Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 377. Australia Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 378. Australia Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 379. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 380. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 381. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 382. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 383. Rest of Asia-Pacific Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 384. Europe Multiple Sclerosis Treatment, by Country USD Million (2025-2030)
  • Table 385. Europe Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 386. Europe Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 387. Europe Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 388. Europe Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 389. Europe Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 390. Germany Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 391. Germany Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 392. Germany Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 393. Germany Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 394. Germany Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 395. France Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 396. France Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 397. France Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 398. France Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 399. France Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 400. Italy Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 401. Italy Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 402. Italy Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 403. Italy Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 404. Italy Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 405. United Kingdom Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 406. United Kingdom Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 407. United Kingdom Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 408. United Kingdom Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 409. United Kingdom Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 410. Netherlands Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 411. Netherlands Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 412. Netherlands Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 413. Netherlands Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 414. Netherlands Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 415. Rest of Europe Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 416. Rest of Europe Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 417. Rest of Europe Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 418. Rest of Europe Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 419. Rest of Europe Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 420. MEA Multiple Sclerosis Treatment, by Country USD Million (2025-2030)
  • Table 421. MEA Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 422. MEA Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 423. MEA Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 424. MEA Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 425. MEA Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 426. Middle East Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 427. Middle East Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 428. Middle East Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 429. Middle East Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 430. Middle East Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 431. Africa Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 432. Africa Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 433. Africa Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 434. Africa Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 435. Africa Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 436. North America Multiple Sclerosis Treatment, by Country USD Million (2025-2030)
  • Table 437. North America Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 438. North America Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 439. North America Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 440. North America Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 441. North America Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 442. United States Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 443. United States Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 444. United States Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 445. United States Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 446. United States Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 447. Canada Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 448. Canada Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 449. Canada Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 450. Canada Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 451. Canada Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 452. Mexico Multiple Sclerosis Treatment, by Type USD Million (2025-2030)
  • Table 453. Mexico Multiple Sclerosis Treatment, by Application USD Million (2025-2030)
  • Table 454. Mexico Multiple Sclerosis Treatment, by Multiple Sclerosis USD Million (2025-2030)
  • Table 455. Mexico Multiple Sclerosis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 456. Mexico Multiple Sclerosis Treatment, by Administration USD Million (2025-2030)
  • Table 457. Multiple Sclerosis Treatment Sales: by Type(K Units)
  • Table 458. Multiple Sclerosis Treatment Sales Immunomodulators (Ponesimod, Glatopa, Copaxone, Others) , by Region K Units (2025-2030)
  • Table 459. Multiple Sclerosis Treatment Sales Immunosuppressant (Cladribine, Others) , by Region K Units (2025-2030)
  • Table 460. Multiple Sclerosis Treatment Sales Corticosteroids (Prednisone, Methylprednisolone) , by Region K Units (2025-2030)
  • Table 461. Multiple Sclerosis Treatment Sales Beta interferons (Betaseron, Others) , by Region K Units (2025-2030)
  • Table 462. Multiple Sclerosis Treatment Sales: by Application(K Units)
  • Table 463. Multiple Sclerosis Treatment Sales Veterinary Hospitals , by Region K Units (2025-2030)
  • Table 464. Multiple Sclerosis Treatment Sales Veterinary Clinics , by Region K Units (2025-2030)
  • Table 465. Multiple Sclerosis Treatment Sales Research Institutions , by Region K Units (2025-2030)
  • Table 466. Multiple Sclerosis Treatment Sales: by Distribution Channel(K Units)
  • Table 467. Multiple Sclerosis Treatment Sales Healthcare Providers , by Region K Units (2025-2030)
  • Table 468. Multiple Sclerosis Treatment Sales Online Pharmacies , by Region K Units (2025-2030)
  • Table 469. Multiple Sclerosis Treatment Sales Medical Clinics , by Region K Units (2025-2030)
  • Table 470. Multiple Sclerosis Treatment Sales Others , by Region K Units (2025-2030)
  • Table 471. South America Multiple Sclerosis Treatment Sales, by Country K Units (2025-2030)
  • Table 472. South America Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 473. South America Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 474. South America Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 475. South America Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 476. South America Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 477. Brazil Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 478. Brazil Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 479. Brazil Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 480. Brazil Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 481. Brazil Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 482. Argentina Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 483. Argentina Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 484. Argentina Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 485. Argentina Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 486. Argentina Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 487. Rest of South America Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 488. Rest of South America Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 489. Rest of South America Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 490. Rest of South America Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 491. Rest of South America Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 492. Asia Pacific Multiple Sclerosis Treatment Sales, by Country K Units (2025-2030)
  • Table 493. Asia Pacific Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 494. Asia Pacific Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 495. Asia Pacific Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 496. Asia Pacific Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 497. Asia Pacific Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 498. China Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 499. China Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 500. China Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 501. China Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 502. China Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 503. Japan Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 504. Japan Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 505. Japan Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 506. Japan Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 507. Japan Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 508. India Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 509. India Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 510. India Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 511. India Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 512. India Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 513. South Korea Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 514. South Korea Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 515. South Korea Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 516. South Korea Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 517. South Korea Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 518. Taiwan Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 519. Taiwan Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 520. Taiwan Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 521. Taiwan Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 522. Taiwan Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 523. Australia Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 524. Australia Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 525. Australia Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 526. Australia Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 527. Australia Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 528. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 529. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 530. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 531. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 532. Rest of Asia-Pacific Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 533. Europe Multiple Sclerosis Treatment Sales, by Country K Units (2025-2030)
  • Table 534. Europe Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 535. Europe Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 536. Europe Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 537. Europe Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 538. Europe Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 539. Germany Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 540. Germany Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 541. Germany Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 542. Germany Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 543. Germany Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 544. France Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 545. France Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 546. France Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 547. France Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 548. France Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 549. Italy Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 550. Italy Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 551. Italy Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 552. Italy Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 553. Italy Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 554. United Kingdom Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 555. United Kingdom Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 556. United Kingdom Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 557. United Kingdom Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 558. United Kingdom Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 559. Netherlands Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 560. Netherlands Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 561. Netherlands Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 562. Netherlands Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 563. Netherlands Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 564. Rest of Europe Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 565. Rest of Europe Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 566. Rest of Europe Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 567. Rest of Europe Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 568. Rest of Europe Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 569. MEA Multiple Sclerosis Treatment Sales, by Country K Units (2025-2030)
  • Table 570. MEA Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 571. MEA Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 572. MEA Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 573. MEA Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 574. MEA Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 575. Middle East Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 576. Middle East Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 577. Middle East Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 578. Middle East Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 579. Middle East Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 580. Africa Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 581. Africa Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 582. Africa Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 583. Africa Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 584. Africa Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 585. North America Multiple Sclerosis Treatment Sales, by Country K Units (2025-2030)
  • Table 586. North America Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 587. North America Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 588. North America Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 589. North America Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 590. North America Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 591. United States Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 592. United States Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 593. United States Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 594. United States Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 595. United States Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 596. Canada Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 597. Canada Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 598. Canada Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 599. Canada Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 600. Canada Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 601. Mexico Multiple Sclerosis Treatment Sales, by Type K Units (2025-2030)
  • Table 602. Mexico Multiple Sclerosis Treatment Sales, by Application K Units (2025-2030)
  • Table 603. Mexico Multiple Sclerosis Treatment Sales, by Multiple Sclerosis K Units (2025-2030)
  • Table 604. Mexico Multiple Sclerosis Treatment Sales, by Distribution Channel K Units (2025-2030)
  • Table 605. Mexico Multiple Sclerosis Treatment Sales, by Administration K Units (2025-2030)
  • Table 606. Multiple Sclerosis Treatment: by Type(USD/Units)
  • Table 607. Research Programs/Design for This Report
  • Table 608. Key Data Information from Secondary Sources
  • Table 609. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Multiple Sclerosis Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Multiple Sclerosis Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Multiple Sclerosis Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 8. Asia Pacific Multiple Sclerosis Treatment Share (%), by Country
  • Figure 9. Europe Multiple Sclerosis Treatment Share (%), by Country
  • Figure 10. MEA Multiple Sclerosis Treatment Share (%), by Country
  • Figure 11. North America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 12. Global Multiple Sclerosis Treatment: by Type K Units (2018-2023)
  • Figure 13. Global Multiple Sclerosis Treatment: by Application K Units (2018-2023)
  • Figure 14. Global Multiple Sclerosis Treatment: by Distribution Channel K Units (2018-2023)
  • Figure 15. South America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 16. Asia Pacific Multiple Sclerosis Treatment Share (%), by Country
  • Figure 17. Europe Multiple Sclerosis Treatment Share (%), by Country
  • Figure 18. MEA Multiple Sclerosis Treatment Share (%), by Country
  • Figure 19. North America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 20. Global Multiple Sclerosis Treatment: by Type USD/Units (2018-2023)
  • Figure 21. Global Multiple Sclerosis Treatment share by Players 2023 (%)
  • Figure 22. Global Multiple Sclerosis Treatment share by Players (Top 3) 2023(%)
  • Figure 23. Global Multiple Sclerosis Treatment share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva (Israel) Revenue: by Geography 2023
  • Figure 27. Biogen(United States) Revenue, Net Income and Gross profit
  • Figure 28. Biogen(United States) Revenue: by Geography 2023
  • Figure 29. Genzyme (Sanofi) Revenue, Net Income and Gross profit
  • Figure 30. Genzyme (Sanofi) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline(United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline(United Kingdom) Revenue: by Geography 2023
  • Figure 33. Merck Serono(Germany) Revenue, Net Income and Gross profit
  • Figure 34. Merck Serono(Germany) Revenue: by Geography 2023
  • Figure 35. Novartis(Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis(Switzerland) Revenue: by Geography 2023
  • Figure 37. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer (United States) Revenue: by Geography 2023
  • Figure 39. Abbvie (United States) Revenue, Net Income and Gross profit
  • Figure 40. Abbvie (United States) Revenue: by Geography 2023
  • Figure 41. Global Multiple Sclerosis Treatment: by Type USD Million (2025-2030)
  • Figure 42. Global Multiple Sclerosis Treatment: by Application USD Million (2025-2030)
  • Figure 43. Global Multiple Sclerosis Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 44. South America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 45. Asia Pacific Multiple Sclerosis Treatment Share (%), by Country
  • Figure 46. Europe Multiple Sclerosis Treatment Share (%), by Country
  • Figure 47. MEA Multiple Sclerosis Treatment Share (%), by Country
  • Figure 48. North America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 49. Global Multiple Sclerosis Treatment: by Type K Units (2025-2030)
  • Figure 50. Global Multiple Sclerosis Treatment: by Application K Units (2025-2030)
  • Figure 51. Global Multiple Sclerosis Treatment: by Distribution Channel K Units (2025-2030)
  • Figure 52. South America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 53. Asia Pacific Multiple Sclerosis Treatment Share (%), by Country
  • Figure 54. Europe Multiple Sclerosis Treatment Share (%), by Country
  • Figure 55. MEA Multiple Sclerosis Treatment Share (%), by Country
  • Figure 56. North America Multiple Sclerosis Treatment Share (%), by Country
  • Figure 57. Global Multiple Sclerosis Treatment: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Teva (Israel)
  • Biogen(United States)
  • Genzyme (Sanofi)
  • GlaxoSmithKline(United Kingdom)
  • Merck Serono(Germany)
  • Novartis(Switzerland)
  • Pfizer (United States)
  • Abbvie (United States)
Additional players considered in the study are as follows:
Acorda Therapeutics(United States) , Bayer HealthCare (Germany)
Select User Access Type

Key Highlights of Report


Apr 2024 203 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Multiple Sclerosis Treatment Market research Quantitative research analysis
Global Multiple Sclerosis Treatment Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Teva (Israel), Biogen(United States), Genzyme (Sanofi), GlaxoSmithKline(United Kingdom), Merck Serono(Germany), Novartis(Switzerland), Pfizer (United States) and Abbvie (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The Growing Number Of Multiple Sclerosis Incidences key Driving Factor of Growth" is seen as one of major influencing trends for Multiple Sclerosis Treatment Market during projected period 2023-2030.
The Multiple Sclerosis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Multiple Sclerosis Treatment Market research Report?

Have a Query? Click Here

Other Related Reports

IBS Treatment Comprehensive Study by Type (IBS-D, IBS-C, IBS-M), Application (Hospitals, Clinics, Research Laboratories), Drug (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others), ...
$ 3450
Antibody Drug Conjugates Comprehensive Study by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), Technology (Cleavable Linker, Non-Cleavable Linker), Drugs Type (A...
$ 3450
Swine Diseases Treatment Comprehensive Study by Type (Drugs, Vaccines), Application (Private Veterinary Hospitals, Private Veterinary Pharmacies, Government Veterinary Clinics, Others), Drugs (Anti-I...
$ 3750
Patient Lateral Transfer Comprehensive Study by Type (Air-assisted Lateral Transfer Mattress (Regular Mattress, Split-leg Mattress, Half Mattress), Air-assisted Lateral Transfer Mattress (Reusable Ai...
$ 3750
Clinical Workflow Solution Comprehensive Study by Type (Data Integration, EMR Integration, Nurse Call Systems, Unified Communications, Care Solutions, Patient Flow Management Enterprise Solutions), A...
$ 3650
Renal Function Test Comprehensive Study by Type (Disposables, Reagents, Dipsticks, Other Products), Application (Hospitals, Clinics, Diagnostic Laboratories, Others), Parameters (Serum Urea (15-45 mg...
$ 3750